Related Experiment Videos
[Neuromuscular blockade using vecuronium in dermatomyositis]
P Mair1, G Mitterschiffthaler, E Hohlböck
1Klinik für Anaesthesie und Allgemeine Intensivmedizin, Universität Innsbruck.
Der Anaesthesist
|November 1, 1989
Summary
Dermatomyositis did not increase sensitivity to vecuronium, a neuromuscular blocker. Recovery time was prolonged, but neostigmine antagonism was safe, suggesting careful anesthetic management is possible.
Area of Science:
- Anesthesiology
- Neuromuscular Pharmacology
Background:
- Dermatomyositis is an inflammatory myopathy that can affect neuromuscular function.
- Previous literature suggested potential increased sensitivity to neuromuscular blocking agents in dermatomyositis patients.
Observation:
- A single patient with dermatomyositis received vecuronium for neuromuscular blockade.
- Dosage and response were monitored, along with onset, duration, and recovery times.
Findings:
- Vecuronium demonstrated dose-dependent neuromuscular blockade (0.08 mg/kg for 90%, 0.12 mg/kg for 100%) without enhanced sensitivity.
- Onset and duration of action were within normal limits.
- Spontaneous recovery was prolonged, but antagonism with neostigmine was uneventful despite potential hazards.
Implications:
- Dermatomyositis may not necessitate altered vecuronium dosing strategies.
- Anesthetic management, including neostigmine use for antagonism, appears feasible in dermatomyositis patients.
- Further research is warranted to fully understand neuromuscular blockade implications in dermatomyositis.